semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Type 1 Diabetes diabetes type 1 >18 years old patient having a smartphone, who are familiar with its use  previous or actual use of a diabetes application pregnant
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Ischemic Cardiomyopathy Non-ischemic Cardiomyopathy Heart Failure Ambulatory Patients with a diagnosis of ischemic and non-ischemic cardiomyopathy with a measured EF <35%, class III as defined by the NYHA with ICD and who receive optimal pharmacological therapy  Heart Failure class I, II, IV atrial fibrillation any significant valvular disease chronic obstructive pulmonary disease who treated with inhaled β2 agonist significant kidney disease with eGFR <30% severe uncontrolled electrolyte abnormalities prior allergic reaction to Salbutamol Pregnancy and nursing women
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 21.0-65.0,  Type 1 Diabetes Mellitus Patient must be aged between 21 (inclusive) and 65 years old. The age of 21 has been chosen because this trial is supported by a US Foundation Patient must have been clinically diagnosed with Type 1 diabetes mellitus. For an individual to be enrolled at least one criterion from each list must be met for documented hyperglycemia (at least 1 must be met) Fasting glucose ≥126 mg/dL confirmed Two-hour OGTT glucose ≥200 mg/dL confirmed HbA1c ≥6.5% documented confirmed Random glucose ≥200 mg/dL with symptoms  Diabetic ketoacidosis within the 6 months prior to enrollment Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment Pregnancy, breast feeding, or intention of becoming pregnant Uncontrolled arterial hypertension (diastolic blood pressure >90 mmHg and/or systolic blood pressure >160 mmHg) Conditions which may increase the risk of hypoglycemia such as uncontrolled coronary artery disease during the previous year (e.g. history of myocardial infarction, acute coronary syndrome, therapeutic coronary intervention, coronary bypass or stenting procedure, stable or unstable angina, episode of chest pain of cardiac etiology with documented EKG changes, or positive stress test or catheterization with coronary blockages >50%), congestive heart failure, history of cerebrovascular event, seizure disorder, syncope, adrenal insufficiency, neurologic disease or atrial fibrillation History of a systemic or deep tissue infection with methicillin-resistant staph aureus or Candida albicans Use of a device that may pose electromagnetic compatibility issues and/or radiofrequency interference with the DexCom CGM (implantable cardioverter-defibrillator, electronic pacemaker, neurostimulator, intrathecal pump, and cochlear implants) Anticoagulant therapy other than aspirin Oral steroids Medical condition requiring use of an acetaminophen-containing medication that cannot be withheld for the study admissions
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 21.0-65.0,  Type 1 Diabetes Mellitus Patient must be aged between 21 (inclusive) and 65 years old. The age of 21 has been chosen because this trial is supported by a US Foundation Patient must have been clinically diagnosed with Type 1 diabetes mellitus. For an individual to be enrolled at least one criterion from each list must be met for documented hyperglycemia (at least 1 must be met) Fasting glucose ≥126 mg/dL confirmed Two-hour Oral Glucose Tolerance Test (OGTT) glucose ≥200 mg/dL confirmed HbA1c ≥6.5% documented confirmed Random glucose ≥200 mg/dL with symptoms  Diabetic ketoacidosis within the 6 months prior to enrollment Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment Pregnancy, breast feeding, or intention of becoming pregnant Uncontrolled arterial hypertension (diastolic blood pressure >90 mmHg and/or systolic blood pressure >160 mmHg) Conditions which may increase the risk of hypoglycemia such as uncontrolled coronary artery disease during the previous year (e.g. history of myocardial infarction, acute coronary syndrome, therapeutic coronary intervention, coronary bypass or stenting procedure, stable or unstable angina, episode of chest pain of cardiac etiology with documented EKG changes, or positive stress test or catheterization with coronary blockages >50%), congestive heart failure, history of cerebrovascular event, seizure disorder, syncope, adrenal insufficiency, neurologic disease or atrial fibrillation History of a systemic or deep tissue infection with methicillin-resistant staph aureus or Candida albicans Use of a device that may pose electromagnetic compatibility issues and/or radiofrequency interference with the DexCom CGM (implantable cardioverter-defibrillator, electronic pacemaker, neurostimulator, intrathecal pump, and cochlear implants) Anticoagulant therapy other than aspirin Oral steroids Medical condition requiring use of an acetaminophen-containing medication that cannot be withheld for the study admissions
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sudden Cardiac Death Ventricular Fibrillation Ventricular Tachycardia Ventricular Dysfunction Myocardial Ischemia Patients who have undergone CABG surgery during current hospitalization Patients who have an ejection fraction ≤ 35% following the surgery Patients who have dilated cardiomyopathy or prior myocardial infarction Patients who are prescribed a wearable defibrillator following surgery Patient who are at least 18 years old  Patients who have an active ICD Patients who have an active unipolar pacemaker Patients having a chest circumference over 56 inches or under 26 inches Patients who are unable to consent or unwilling to wear the WCD after discharge or who do not agree to be contacted at 90 days Patients with a mental, visual, physical or auditory deficit that could impair their ability to properly interact with a wearable defibrillator Patients participating in another clinical study with mortality as the primary endpoint Patients unable to use a wearable defibrillator due to physical conditions (bandages preventing electrode contact, physical deformities preventing electrode contact, dextrocardia, etc.) Patients who have decided to forgo resuscitation
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 2.0-70.0,  Healthy Aged 2 to 70 years on the day of Informed consent form signed by subjects and parent/guardian Subjects and parents/guardians able to attend all scheduled visits and comply with all study procedures  Subjects with any pneumococcal vaccine before vaccination History of pneumococcal infection Women in pregnancy or lactation period in trial period Allergic history or any SAE after vaccination, such as allergy, urticaria, dyspnea, angioedema, celialgia Known or suspected immune dysfunction, including persons with congenital immunodeficiency or persons with HIV positive Functional or anatomic asplenia Patients treated with chemotherapy in past 5 years or administered with immunosuppressive agents, cytotoxicity factor or corticosteroids in the 6 months preceding the vaccine trial Receipt of blood or blood-derived products in the 3 months preceding vaccination Participation in another clinical study investigating a vaccine, drug in the 30 days preceding vaccination Receipt of any live virus vaccine in the 30 days preceding vaccination
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Dyspnea adults age 19 or older 2. diagnosed with chronic heart failure 3. experiencing shortness of breath at rest or with activities 4. experiencing shortness of breath that limits their activity 5. cognitively intact indicated by being able to describe what participation in the study will involve 6. have a telephone; AND 7. reside in a rural area either large rural (10,000-49,000 residents), small rural (2500 residents), or isolated (< 2499 residents) area  myocardial infarction or coronary bypass surgery within the last three months 2. active chest pain 3. uncontrolled arrhythmias (atrial fibrillation or ventricular tachycardia) 4. on the transplant list or having a ventricular assist device 5. orthopedic or neurological conditions that would impact muscle strength or interfere with the 6 minute walk test (6-MWT) (amputation, severe arthritis, Parkinson's, stroke, or severe neuropathy) 6. history of severe COPD; AND 7. history of sleep breathing disorder
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Diabetes Mellitus, Type 1 Type 1 Diabetes for five years or more* Age 40 years or above 0 =< HbA1c <10.0% (53 mmol/mol) AND 3 or more of the following ten CardioVascular Disease (CVD) risk factors BMI >27 kg/m^2 Current HbA1c >8.0% (64 mmol/mol) Known CVD/peripheral vascular disease Current smoker Estimated glomerular filtration rate (eGFR) <90 ml/min per 1.73 m^3 Confirmed micro  eGFR < 45 ml/min/1.73m2 woman of childbearing age not on effective contraception Pregnancy and/or lactation Acute coronary syndrome or Stroke/Transient Ischaemic Attack within the last three months NYHA stage 3 or 4 heart failure Significant hypoglycaemia unawareness Impaired cognitive function/ unable to give informed consent Previous carotid surgery/ inability to capture adequate carotid images Estimated glomerular filtration < 45ml/min/1.73m^2 (MDRD) Gastroparesis
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 10.0-17.0,  Diabetes Diabetes Mellitus, Type 1 Signed informed consent obtained before any trial-related activities according to local requirements. (Trial-related activities are any procedure that would not have been performed during normal management of the subject) The subject must have completed the trial BIAsp-1240
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 21.0-45.0,  Type 1 Diabetes Mellitus To be eligible for the study, all subjects must meet the following 1. Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year. The diagnosis of type 1 diabetes is based on the investigator's judgment; Cpeptide level and antibody determinations are not needed. 2. Age 21 years to less than 45.0 years 3. Subject has used a downloadable insulin pump for at least 3 months 4. Subject understands the study protocol and agrees to comply with it 5. Informed Consent Form signed 6. A Personal Home computer with internet access (must have access to a PC for uploading, not a Mac)  Subjects who meet any of the following are not eligible for the study: 1. The presence of a significant medical disorder that in the judgment of the investigator will affect the wearing of the sensors or the completion of any aspect of the protocol. 2. The presence of any of the following diseases Asthma if treated with systemic or inhaled corticosteroids in the last 6 months Cystic fibrosis Other major illness that in the judgment of the investigator might interfere with the completion of the protocol Adequately treated thyroid disease and celiac disease do not subjects from enrollment 3. Inpatient psychiatric treatment in the past 6 months 4. Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study. 5. Pregnancy, breast feeding, or intention of becoming pregnant in the next 2 months. 6. Weight less than 26 kg 7. Renal failure or peritoneal dialysis 8. History of heart disease 9. The use of beta-blockers 10. History of cerebrovascular disease, or non-hypoglycemic seizures, or intolerance of glucagon treatment. 11. History of a hypoglycemic seizure within 6 months of enrollment
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Type II Diabetes Mellitus Diagnosed as type 2 diabetes mellitus patient at least 12 weeks before the study Stable diet and exercise program for at least 8 weeks before the study On a stable dose of at least 1500 mg/day metformin monotherapy or at least 1000 mg/day metformin monotherapy for the subject who can not titrate up to 1500 mg/day due to safety concern of metformin BMI of 20.0 to 45.0 kg/m2 A HbA1c value between 7.0 and 10.0% at screening AND does not meet any of discontinuation on fasting plasma glucose  Type 1 diabetes mellitus Proliferative diabetic retinopathy Receiving insulin within 12 weeks prior to the study History of clinically significant renal disease(s) Significant dysuria caused by a neurogenic bladder or a benign prostate hypertrophy etc Urinary tract infection or genital infection Continuous use of systemic corticosteroids, immunosuppressants, or loop diuretics History of cerebrovascular attack, unstable angina, myocardial infarction, angioplasty, serious cardiac diseases within 12 weeks prior to the study Severe infection, serious trauma, or perioperative subject Known or suspected hypersensitivity to ASP1941
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 50.0-80.0,  Chronic Obstructive Pulmonary Disease the patients with clinical diagnosis of COPD presenting FEV1/FVC < 70% and FEV1 < 80% predicted by pulmonary function observed and were classified as patients with moderate to very severe obstruction (RABE et al., 2008) clinically stable with no history infection or exacerbation of the respiratory symptoms or a change in medication for two months preceding the study the patients were non oxygen dependent, smokers or former smokers  patients with clinical diagnosis of COPD presenting FEV1/FVC ≥ 70% FEV1 ≥ 80% predicted (RABE et al., 2008) who present respiratory, cardiac, rheumatic, musculoskeletal, orthopedic and neuromuscular disorders associated that may prevent them of the testing and intervention proposed that are experiencing swelling in lower limbs that change the type of medication during the study uncontrolled hypertension patients saturation below 90% at rest and did not agree to sign the formal consent form proposed
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Diabetes Mellitus Type II Diabetes Mellitus Age between 18-65 years BMI < 40 In overall good health  History of coronary atherosclerotic disease, MI, CVA, or significant peripheral vascular disease BMI > 40 Subjects with diastolic blood pressures greater than 100 mm Hg while on anti-hypertensive medications, or systolic blood pressures greater than 160 mm Hg while on anti-hypertensive medications will be excluded Current alcohol or drug abuse Subjects taking other medications (except thyroid supplements, oral hyperglycemic agents and insulin) will be excluded Subjects who are on medications that cannot be discontinued such as anti-depressants, anti-seizure medications, etc that may interfere with salt and water handling will not be studied